Showing 1111-1120 of 5128 results for "".
- First Subject Dosed in Phase 1 Clinical Study of NM26 for ADhttps://practicaldermatology.com/news/first-subject-dosed-in-phase-1-clinical-study-of-nm26-for-ad/2461718/The first subject has been dosed in the Phase 1 clinical study of Numab Therapeutics’ NM26-2198, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis (AD). This marks the beginning of a combined single ascending dose (SAD) and multip
- Rare Skin Disease Update: Abeona's EB-101 Performs Well in a Phase 3 study of RDEBhttps://practicaldermatology.com/news/rare-skin-disease-update-abeonas-eb-101-performs-well-in-a-phase-3-study-of-rdeb/2461715/Abeona Therapeutics Inc.’s investigational EB-101 performed well in a Phase 3 study of recessive dystrophic epidermolysis bullosa (RDEB). Both co-primary endpoints were met, with the majority (81.4%) of randomized EB-101–treated wounds demonstrating ≥50% healing compared
- American Academy of Dermatology Survey Shows Generation Z Adults are Unfamiliar with Sunburn and Tanning Riskshttps://practicaldermatology.com/news/american-academy-of-dermatology-survey-shows-generation-z-adults-are-unfamiliar-with-sunburn-and-tanning-risks/2461708/A recent American Academy of Dermatology survey of more than 1,000 US adults revealed that many Generation Z adults, ages 18-25, are unaware of the risks associated with overexposure to the sun and believe tanning myths, according to an AAD news release. According to the surv
- News You Can Use: MIPS Hardship Exception Available Nowhttps://practicaldermatology.com/news/news-you-can-use-mips-hardship-exception-available-now/2461702/Physicians may now apply for an Extreme and Uncontrollable Circumstances hardship exception to avoid an up to 9% penalty in the Merit-based Incentive Payment System (MIPS) thanks to advocacy from the American Medical Association and organized medicine about the ongoing impacts of the COVID-19 pub
- Online Exclusive: New Practice-changing Research Links ARD to Bacteriahttps://practicaldermatology.com/news/online-exclusive-new-practice-changing-research-links-rad-to-bacteria/2461701/As many as 95% of people undergoing radiation treatment for cancer will develop acute radiation dermatitis (ARD). Little, however, has been known about why this condition occurs, and there are no widely adapted or standardized treatments for preventing severe ARD. New research may chang
- Opzelura Helps Beat AD Itchhttps://practicaldermatology.com/news/opzelura-helps-beat-ad-itch/2461690/Opzelura (ruxolitinib) cream 1.5% showed substantial and rapid itch reduction in patients with mild-moderate Atopic Dermatitis (AD). These data were featured in a poster presentation at the Revolutionizing Atopic Dermatitis (RAD) Conference, held from April 29-May 1 in Washing
- Kerecis Introduces Fish-Skin Graft and Silicone Cover for Wound Treatmenthttps://practicaldermatology.com/news/kerecis-introduces-fish-skin-graft-and-silicone-cover-for-wound-treatment/2461686/Kerecis rolled out MariGen Shield, a treatment which integrates the company’s fish-skin graft with a silicone contact layer for treating chronic and complex wounds. The company also announced the results of a clinical study comparing the effectiveness of the Kerecis fish
- The Melanoma Research Alliance, SPOTMYUV Continue Partnership to Promote Sun Safetyhttps://practicaldermatology.com/news/the-melanoma-research-alliance-spotmyuv-continue-partnership-to-promote-sun-safety/2461685/The Melanoma Research Alliance and SPOTMYUV are renewing their partnership to promote sun safety and effective use of sunscreen. The two organizations will co-develop sun safety and skin cancer prevention materials that empower consumers to protect themselves and those they love from UV
- La Roche-Posay Gives Back: Brand Offers Free Public Screenings in NYChttps://practicaldermatology.com/news/la-roche-posay-gives-back-brand-offers-free-public-screenings-in-nyc/2461678/La Roche-Posay is kicking off Melanoma Awareness Month with free public skin cancer screenings at Hudson Yards on Sunday, April 30th and Monday, May 1st. On Sunday, April 30th and Monday, May 1st (Melanoma Monday,) La Roche-Posay, in partners
- Cynosure Taps New CEOhttps://practicaldermatology.com/news/cynosure-taps-new-ceo/2461676/Nadav Tomer is Cynosure’s new chief executive officer, effective May 1, 2023. He succeeds Todd Tillemans, who will step down and will work closely with Mr. Tomer to ensure a smooth transition. "Nadav has an incredibly strong track record of operation